Abstract | CONTEXT: OBJECTIVE: DESIGN AND SETTINGS: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr. PATIENTS: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled. MAIN OUTCOME MEASURES:
Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval. RESULTS: No difference in vaginal bleeding (mean number of days per year) was noted. Mean change in DeltaBA/DeltaCA, which was 1.25 +/- 0.77 at baseline, was -0.25 +/- 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 +/- 3.15 at study entry and 0.26 +/- 2.71 at 12 months (P = 0.10). Mean ovarian/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred. CONCLUSIONS: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.
|
Authors | Jakub Mieszczak, Elizabeth S Lowe, Paul Plourde, Erica A Eugster |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 93
Issue 7
Pg. 2751-4
(Jul 2008)
ISSN: 0021-972X [Print] United States |
PMID | 18397987
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aromatase Inhibitors
- Nitriles
- Triazoles
- Anastrozole
|
Topics |
- Anastrozole
- Aromatase Inhibitors
(therapeutic use)
- Child
- Child, Preschool
- Female
- Fibrous Dysplasia, Polyostotic
(drug therapy)
- Humans
- Nitriles
(adverse effects, therapeutic use)
- Prospective Studies
- Puberty, Precocious
(drug therapy)
- Triazoles
(adverse effects, therapeutic use)
- Uterine Hemorrhage
(drug therapy)
|